Xspray Pharma AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was SEK 54.5 million compared to SEK 55.22 million a year ago. Basic loss per share from continuing operations was SEK 1.85 compared to SEK 2.48 a year ago. Diluted loss per share from continuing operations was SEK 1.85 compared to SEK 2.48 a year ago.
For the full year, net loss was SEK 179.67 million compared to SEK 131.67 million a year ago. Basic loss per share from continuing operations was SEK 6.76 compared to SEK 6.25 a year ago. Diluted loss per share from continuing operations was SEK 6.76 compared to SEK 6.25 a year ago.